Touyun Biotech Group Limited, an investment holding company, designs, develops, manufactures, and sells packaging products in Hong Kong, the People’s Republic of China, Europe, North and South America, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$0.88|
|52 Week High||HK$0.47|
|52 Week Low||HK$1.75|
|1 Month Change||-2.22%|
|3 Month Change||-3.30%|
|1 Year Change||79.59%|
|3 Year Change||292.86%|
|5 Year Change||-24.14%|
|Change since IPO||287.32%|
Recent News & Updates
Could The China Touyun Tech Group Limited (HKG:1332) Ownership Structure Tell Us Something Useful?
The big shareholder groups in China Touyun Tech Group Limited ( HKG:1332 ) have power over the company. Large companies...
If You Had Bought China Touyun Tech Group (HKG:1332) Shares A Year Ago You'd Have Earned 380% Returns
While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...
|1332||HK Packaging||HK Market|
Return vs Industry: 1332 exceeded the Hong Kong Packaging industry which returned 6.6% over the past year.
Return vs Market: 1332 exceeded the Hong Kong Market which returned 5.9% over the past year.
Stable Share Price: 1332 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: 1332's weekly volatility (10%) has been stable over the past year.
About the Company
Touyun Biotech Group Limited, an investment holding company, designs, develops, manufactures, and sells packaging products in Hong Kong, the People’s Republic of China, Europe, North and South America, and internationally. It operates through four segments: QR Code Business, Packaging Products, Treasury Investment, and Chlamydomonas Reinhardtii Product Business. The QR Code Business segment provides QR codes on product packaging and solutions; and online advertising display services.
Touyun Biotech Group Fundamentals Summary
|1332 fundamental statistics|
Is 1332 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1332 income statement (TTM)|
|Cost of Revenue||HK$146.36m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.053|
|Net Profit Margin||-58.66%|
How did 1332 perform over the long term?See historical performance and comparison
Is Touyun Biotech Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 1332's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 1332's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 1332 is unprofitable, so we can't compare its PE Ratio to the Hong Kong Packaging industry average.
PE vs Market: 1332 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1332's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1332 is overvalued based on its PB Ratio (5.3x) compared to the HK Packaging industry average (0.6x).
How is Touyun Biotech Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Materials industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Touyun Biotech Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Touyun Biotech Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1332 is currently unprofitable.
Growing Profit Margin: 1332 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 1332 is unprofitable, but has reduced losses over the past 5 years at a rate of 38.9% per year.
Accelerating Growth: Unable to compare 1332's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1332 is unprofitable, making it difficult to compare its past year earnings growth to the Packaging industry (31.8%).
Return on Equity
High ROE: 1332 has a negative Return on Equity (-26.05%), as it is currently unprofitable.
How is Touyun Biotech Group's financial position?
Financial Position Analysis
Short Term Liabilities: 1332's short term assets (HK$540.0M) exceed its short term liabilities (HK$511.5M).
Long Term Liabilities: 1332's short term assets (HK$540.0M) exceed its long term liabilities (HK$6.1M).
Debt to Equity History and Analysis
Debt Level: 1332's debt to equity ratio (60.6%) is considered high.
Reducing Debt: 1332's debt to equity ratio has increased from 0.01% to 60.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1332 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 1332 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 9% each year
What is Touyun Biotech Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1332's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1332's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1332's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1332's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1332's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Touyun Biotech Group has no CEO, or we have no data on them.
Experienced Board: 1332's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Touyun Biotech Group Limited's employee growth, exchange listings and data sources
- Name: Touyun Biotech Group Limited
- Ticker: 1332
- Exchange: SEHK
- Founded: 1989
- Industry: Paper Packaging
- Sector: Materials
- Market Cap: HK$2.467b
- Shares outstanding: 2.80b
- Website: https://touyunbiotech.com.hk
Number of Employees
- Touyun Biotech Group Limited
- Kwan Chart Tower
- 12th Floor
- Wan Chai
- Hong Kong
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/23 10:03|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.